We provide you with 20 years of free, institutional-grade data for APRE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of APRE. Explore the full financial landscape of APRE stock.
| Reported Date | CIK | Ticker | Type |
|---|
Aprea Therapeutics, Inc(NASDAQ:APRE) 
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical d...
Website: http://www.aprea.com
Founded: 2006
IPO Price: $15 (Oct 03, 2019)
Full Time Employees: 13
CEO: Christian S. Schade
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about APRE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.